Search Results
Department of Clinical Sciences, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
Search for other papers by Grace Kong in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
, there is relatively high consistency in the effectiveness of PRRT for gastroenteropancreatic (GEP) NET, with an encouraging 40% response rate (RR), 80% disease control rate (DCR) and long overall survival (OS) ( Brabander et al . 2017 , Hicks et al
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Wei Deng in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St.Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Merete Krogh in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
Introduction High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are defined by the presence of neuroendocrine phenotype and a high proliferation rate (Ki-67 > 20%). The HG NEN entity consists of well
Search for other papers by Andrew McDonald in
Google Scholar
PubMed
Search for other papers by Vaidehi Avadhani in
Google Scholar
PubMed
Search for other papers by Gabriela Oprea-Ilies in
Google Scholar
PubMed
Search for other papers by Katerina Zakka in
Google Scholar
PubMed
Search for other papers by Gregory B Lesinski in
Google Scholar
PubMed
Search for other papers by Olumide B Gbolahan in
Google Scholar
PubMed
Search for other papers by Olatunji Alese in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) system are a heterogeneous group of rare malignancies. While the incidence of NENs was relatively low, with 6.98 cases per 100,000 adults in 2012, the incidence
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Florian Bösch in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Katharina Brüwer in
Google Scholar
PubMed
Search for other papers by Annelore Altendorf-Hofmann in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by C Benedikt Westphalen in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Stefan Boeck in
Google Scholar
PubMed
Munich Cancer Registry (MCR) of the Munich Tumour Centre (TZM), Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Gabriele Schubert-Fritschle in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Jens Werner in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Volker Heinemann in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Kirchner in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
, Lawrence et al . 2011 ). Thus, NENs are nowadays as frequent as testicular tumors, Hodgkin’s disease, gliomas and multiple myeloma ( Modlin et al . 2008 ). Gastroenteropancreatic NENs (GEP-NENs) represent the preponderance with primaries localized in the
Search for other papers by Taymeyah Al-Toubah in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Valentina Andreasi in
Google Scholar
PubMed
Search for other papers by Franco Silvestris in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Daniel A Anaya in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors which include NETs of the gastrointestinal tract and pancreas. Tumor grade and differentiation are important prognostic factors. Low
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
, but is not specific for these tumours ( Klöppel et al . 2009 ). Under the electron microscope the NENs show typical neurosecretory granules. This review deals with the classification of the gastroenteropancreatic NENs (GEP-NENs) and discusses briefly
Search for other papers by Nicole Panarelli in
Google Scholar
PubMed
Search for other papers by Kathrin Tyryshkin in
Google Scholar
PubMed
Search for other papers by Justin Jong Mun Wong in
Google Scholar
PubMed
Search for other papers by Adrianna Majewski in
Google Scholar
PubMed
Search for other papers by Xiaojing Yang in
Google Scholar
PubMed
Search for other papers by Theresa Scognamiglio in
Google Scholar
PubMed
Search for other papers by Michelle Kang Kim in
Google Scholar
PubMed
Search for other papers by Kimberly Bogardus in
Google Scholar
PubMed
Search for other papers by Thomas Tuschl in
Google Scholar
PubMed
Search for other papers by Yao-Tseng Chen in
Google Scholar
PubMed
HHMI, Laboratory of RNA Molecular Biology, The Rockefeller University, New York, New York, USA
Search for other papers by Neil Renwick in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasingly common and clinically diverse neoplasms ( Yao et al . 2008 , Lawrence et al . 2011 ) that are challenging to evaluate histologically ( Klimstra 2016
Search for other papers by Bristi Basu in
Google Scholar
PubMed
Search for other papers by Bhawna Sirohi in
Google Scholar
PubMed
Search for other papers by Pippa Corrie in
Google Scholar
PubMed
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumours . Journal of Nuclear Medicine 47 223 – 233 . Faiss S Scherubl H Riecken EO
Institute of Pathology, Department of Internal Medicine, Department of Pathology, Institute of Pathology, Institute of Pathology, Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany
Search for other papers by Atsuko Kasajima in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Silvia Darb-Esfahani in
Google Scholar
PubMed
Search for other papers by Aurelia Noske in
Google Scholar
PubMed
Institute of Pathology, Department of Internal Medicine, Department of Pathology, Institute of Pathology, Institute of Pathology, Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany
Search for other papers by Albrecht Stenzinger in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
Search for other papers by Manfred Dietel in
Google Scholar
PubMed
Search for other papers by Carsten Denkert in
Google Scholar
PubMed
Search for other papers by Christoph Röcken in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Institute of Pathology, Department of Internal Medicine, Department of Pathology, Institute of Pathology, Institute of Pathology, Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany
Search for other papers by Wilko Weichert in
Google Scholar
PubMed
Introduction With an incidence rate of about 2.5–5 cases per 100 000 person-years, gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rather rare neoplasms when compared with adenocarcinomas of the same locations ( Modlin et al . 2008
Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK
Division of Endocrinology and Investigative Medicine, Imperial College London, Hammersmith Campus, London, UK
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK
Centre for Applied Biological and Exercise Sciences, Coventry University, Coventry, UK
Search for other papers by Martin O Weickert in
Google Scholar
PubMed
Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK
Centre for Applied Biological and Exercise Sciences, Coventry University, Coventry, UK
Search for other papers by Harpal S Randeva in
Google Scholar
PubMed
Division of Pathophysiology, National and Kapodistrian University of Athens Medical School, Athens, Greece
Oxford Center for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
Introduction Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are considered to be relatively rare, with an estimated incidence of 3–5 cases per 100,000 inhabitants; however, recent data indicate that their prevalence is increasing